The value of genetic testing: beyond clinical utility. Read more about The value of genetic testing: beyond clinical utility.
Payer decision making for next-generation sequencing-based genetic tests: insights from cell-free DNA prenatal screening. Read more about Payer decision making for next-generation sequencing-based genetic tests: insights from cell-free DNA prenatal screening.
Electronic health record interventions at the point of care improve documentation of care processes and decrease orders for genetic tests commonly ordered by nongeneticists. Read more about Electronic health record interventions at the point of care improve documentation of care processes and decrease orders for genetic tests commonly ordered by nongeneticists.
What are people willing to pay for whole-genome sequencing information, and who decides what they receive? Read more about What are people willing to pay for whole-genome sequencing information, and who decides what they receive?
Economic evidence on identifying clinically actionable findings with whole-genome sequencing: a scoping review. Read more about Economic evidence on identifying clinically actionable findings with whole-genome sequencing: a scoping review.
PMS2 monoallelic mutation carriers: the known unknown. Read more about PMS2 monoallelic mutation carriers: the known unknown.
Key emerging themes for assessing the cost-effectiveness of reporting incidental findings. Read more about Key emerging themes for assessing the cost-effectiveness of reporting incidental findings.
Assessing multilevel determinants of adoption and implementation of genomic medicine: an organizational mixed-methods approach. Read more about Assessing multilevel determinants of adoption and implementation of genomic medicine: an organizational mixed-methods approach.
Whole-exome sequencing in undiagnosed genetic diseases: interpreting 119 trios. Read more about Whole-exome sequencing in undiagnosed genetic diseases: interpreting 119 trios.
